Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.49 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.49 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.47 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.47 |
| ▸ | CPT2 | P23786 | 1/20 | 0.44 |
| ▸ | CPT1A | P50416 | 1/20 | 0.44 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.44 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258782 | 1.00 | FAAH (0.65) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL258407 | 1.00 | FAAH (0.65) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL258663 | 1.00 | FAAH (0.65) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL258528 | 1.00 | FAAH (0.65) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL258719 | 1.00 | FAAH (0.65) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL28619599 | 0.98 | FAAH (0.62) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL28475200 | 0.98 | FAAH (0.62) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL6561935 | 0.91 | FAAH (0.58) | FAAHMEN1KMT2AMAPK1ASAH2 | |
| SCHEMBL11049958 | 0.91 | FAAH (0.58) | FAAHMEN1KMT2AMAPK1ASAH2 | |
| SCHEMBL4622252 | 0.84 | KMT2A (0.44) | FAAHMEN1KMT2AMAPK1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260043065-A1 | Methods of Administering 3,4-Diaminopyridine | SERB SA (BE) | 2026-02-12 | — | — | US | disclosed |
| US-20240316050-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH LOW BH4 BIOAVAILABILITY | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-09-26 | — | — | US | disclosed |
| US-11873525-B2 | Methods of administering 3,4-diaminopridine | SERB SA (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11845977-B2 | Methods of administering 3,4-diaminopridine | SERB SA (BE) | 2023-12-19 | — | — | US | disclosed |
| US-11840515-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c | ACADIA PHARMACEUTICALS INC. (US) | 2023-12-12 | — | — | US | disclosed |
| EP-4262806-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH LOW BH4 BIOAVAILABILITY | Oxford University Innovation Limited (GB) | 2023-10-25 | — | — | EP | disclosed |
| US-20230313265-A1 | Methods of Administering 3,4-Diaminopridine | SERB SA (BE) | 2023-10-05 | — | — | US | disclosed |
| US-20230295685-A1 | Methods of Administering 3,4-Diaminopridine | SERB SA (BE) | 2023-09-21 | — | — | US | disclosed |
| CN-116723842-A | Treatment of conditions associated with low BH4 bioavailability | 牛津大学科技创新有限公司 | 2023-09-08 | — | — | CN | disclosed |
| US-20230034700-A1 | Methods of Administering 3,4-Diaminopyridine | SERB SA (BE) | 2023-02-02 | — | — | US | disclosed |
| WO-2005113543-A1 | CRYSTALLINE FORMS OF A PYRIDINYL-SULFONAMIDE AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | SPEEDEL PHARMA AG (CH) | 2005-12-01 | — | — | WO | disclosed |
| EP-1595880-A1 | Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists | Speedel Pharma AG (CH) | 2005-11-16 | — | — | EP | disclosed |
| US-20050147629-A1 | Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant | NODEN PHARMA DAC (IE) | 2005-07-07 | — | — | US | disclosed |
| WO-2005058872-A1 | CRYSTALLINE FORMS OF (+)- AND (-)-ERYTHRO-MEFLOQUINE HYDROCHLORIDE | ARAKIS LTD. (GB) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005049000-A2 | TREATMENT OF PHENYLKETONURIAS WITH BH4 | BIOMARIN PHARMACEUTICAL INC. (US) | 2005-06-02 | — | — | WO | disclosed |
| EP-1517682-A1 | PHARMACEUTICAL FORMULATION COMPRISING NON-PEPTIDE RENIN INHIBITOR AND SURFACTANT | Speedel Pharma AG (CH) | 2005-03-30 | — | — | EP | disclosed |
| US-20040077232-A1 | Pharmaceutical compositions | EBNER ANDREAS (DE) | 2004-04-22 | — | — | US | disclosed |
| WO-2004002466-A1 | PHARMACEUTICAL FORMULATION COMPRISING NON-PEPTIDE RENIN INHIBITOR AND SURFACTANT | SPEEDEL PHARMA AG (CH) | 2004-01-08 | — | — | WO | disclosed |
| EP-1372611-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY WATER-SOLUBLE ACTIVE INGREDIENT, A SURFACTANT AND A WATER-SOLUBLE POLYMER | Novartis AG (CH) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002076432-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY WATER-SOLUBLE ACTIVE INGREDIENT, A SURFACTANT AND A WATER-SOLUBLE POLYMER | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295685-A1 | Methods of Administering 3,4-Diaminopridine | NAT1, SAT1, AADAC | FAAH 1128/4885MEN1 3536/4885KMT2A 1791/4885 |
| US-11840515-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c | NR3C2, NR2C2, CYP4A22 | FAAH 4301/4885MEN1 4247/4885KMT2A 797/4885 |
| US-20260043065-A1 | Methods of Administering 3,4-Diaminopyridine | NAT1, SAT1, NANS | FAAH 2280/4885MEN1 2192/4885KMT2A 1550/4885 |
| US-20230313265-A1 | Methods of Administering 3,4-Diaminopridine | NAT1, SAT1, AADAC | FAAH 1128/4885MEN1 3536/4885KMT2A 1791/4885 |
| US-11873525-B2 | Methods of administering 3,4-diaminopridine | NAT1, SAT1, AADAC | FAAH 1128/4885MEN1 3536/4885KMT2A 1791/4885 |
| US-11845977-B2 | Methods of administering 3,4-diaminopridine | NAT1, SAT1, AADAC | FAAH 1128/4885MEN1 3536/4885KMT2A 1791/4885 |
| US-20230034700-A1 | Methods of Administering 3,4-Diaminopyridine | NAT1, NAT10, SAT1 | FAAH 1374/4885MEN1 3616/4885KMT2A 1691/4885 |
| US-20050147629-A1 | Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant | REN, AGT, ACE | FAAH 529/4885MEN1 863/4885KMT2A 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.